Published in Mol Immunol on March 16, 2000
The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J Immunol (2006) 3.62
Acute septic arthritis. Clin Microbiol Rev (2002) 2.17
Further characterization of complement regulator-acquiring surface proteins of Borrelia burgdorferi. Infect Immun (2001) 2.02
Outer membrane proteins of pathogenic spirochetes. FEMS Microbiol Rev (2004) 1.87
LfhA, a novel factor H-binding protein of Leptospira interrogans. Infect Immun (2006) 1.61
Comparative genomics identifies the genetic islands that distinguish Neisseria meningitidis, the agent of cerebrospinal meningitis, from other Neisseria species. Infect Immun (2002) 1.55
The yeast Candida albicans binds complement regulators factor H and FHL-1. Infect Immun (2002) 1.28
Identification and functional characterization of complement regulator-acquiring surface protein 1 of the Lyme disease spirochetes Borrelia afzelii and Borrelia garinii. Infect Immun (2005) 1.27
Meningococcal factor H binding proteins in epidemic strains from Africa: implications for vaccine development. PLoS Negl Trop Dis (2011) 1.27
Mechanisms of resistance of Porphyromonas gingivalis to killing by serum complement. Infect Immun (2006) 1.17
The UspA2 protein of Moraxella catarrhalis is directly involved in the expression of serum resistance. Infect Immun (2005) 1.16
Borrelia recurrentis employs a novel multifunctional surface protein with anti-complement, anti-opsonic and invasive potential to escape innate immunity. PLoS One (2009) 1.05
Borrelia burgdorferi complement regulator-acquiring surface protein 2 does not contribute to complement resistance or host infectivity. PLoS One (2008) 1.05
Human pathogenic Borrelia spielmanii sp. nov. resists complement-mediated killing by direct binding of immune regulators factor H and factor H-like protein 1. Infect Immun (2007) 1.04
Defining targets for complement components C4b and C3b on the pathogenic neisseriae. Infect Immun (2007) 1.03
A novel lectin, DltA, is required for expression of a full serum resistance phenotype in Haemophilus ducreyi. Infect Immun (2004) 1.02
Killing of dsrA mutants of Haemophilus ducreyi by normal human serum occurs via the classical complement pathway and is initiated by immunoglobulin M binding. Infect Immun (2005) 1.02
The Neisseria lipooligosaccharide-specific alpha-2,3-sialyltransferase is a surface-exposed outer membrane protein. Infect Immun (2002) 1.01
Localization of the domains of the Haemophilus ducreyi trimeric autotransporter DsrA involved in serum resistance and binding to the extracellular matrix proteins fibronectin and vitronectin. Infect Immun (2008) 0.98
Borrelia burgdorferi regulates expression of complement regulator-acquiring surface protein 1 during the mammal-tick infection cycle. Infect Immun (2005) 0.98
The opportunistic human pathogenic fungus Aspergillus fumigatus evades the host complement system. Infect Immun (2007) 0.98
Factor H and neisserial pathogenesis. Vaccine (2008) 0.96
The Pathobiology of Neisseria gonorrhoeae Lower Female Genital Tract Infection. Front Microbiol (2011) 0.93
Acquisition of factor H by a novel surface protein on group B Streptococcus promotes complement degradation. FASEB J (2009) 0.93
Deciphering the ligand-binding sites in the Borrelia burgdorferi complement regulator-acquiring surface protein 2 required for interactions with the human immune regulators factor H and factor H-like protein 1. J Biol Chem (2008) 0.92
Features of two proteins of Leptospira interrogans with potential role in host-pathogen interactions. BMC Microbiol (2012) 0.91
Development and evaluation of an improved mouse model of meningococcal colonization. Infect Immun (2003) 0.91
Complement activation and formation of the membrane attack complex on serogroup B Neisseria meningitidis in the presence or absence of serum bactericidal activity. Infect Immun (2002) 0.91
Evolutionary and genomic insights into meningococcal biology. Future Microbiol (2012) 0.90
Binding of human complement regulators FHL-1 and factor H to CRASP-1 orthologs of Borrelia burgdorferi. Wien Klin Wochenschr (2006) 0.89
Expression, purification, cocrystallization and preliminary crystallographic analysis of sucrose octasulfate/human complement regulator factor H SCRs 6-8. Acta Crystallogr Sect F Struct Biol Cryst Commun (2007) 0.89
Differential expression and transcriptional analysis of the alpha-2,3-sialyltransferase gene in pathogenic Neisseria spp. Infect Immun (2006) 0.88
Functional characterization of antibodies against Neisseria gonorrhoeae opacity protein loops. PLoS One (2009) 0.88
Expression of innate immune complement regulators on brain epithelial cells during human bacterial meningitis. J Neuroinflammation (2006) 0.82
Bordetella pertussis acquires resistance to complement-mediated killing in vivo. Infect Immun (2003) 0.82
The rickettsial OmpB β-peptide of Rickettsia conorii is sufficient to facilitate factor H-mediated serum resistance. Infect Immun (2012) 0.80
Molecular characterization of the interaction of Borrelia parkeri and Borrelia turicatae with human complement regulators. Infect Immun (2010) 0.80
Yersinia pestis uses the Ail outer membrane protein to recruit vitronectin. Microbiology (2015) 0.79
Acute septic arthritis: remember gonorrhea. Rheumatol Int (2008) 0.77
How the Knowledge of Interactions between Meningococcus and the Human Immune System Has Been Used to Prepare Effective Neisseria meningitidis Vaccines. J Immunol Res (2015) 0.77
Antimicrobial peptide resistance in Neisseria meningitidis. Biochim Biophys Acta (2015) 0.76
Regulation of capsule in Neisseria meningitidis. Crit Rev Microbiol (2015) 0.76
MetQ of Neisseria gonorrhoeae is a surface expressed antigen that elicits bactericidal and functional blocking antibodies. Infect Immun (2016) 0.75
Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science (1992) 14.70
Genotypic identification of mycobacteria by nucleic acid sequence determination: report of a 2-year experience in a clinical laboratory. J Clin Microbiol (1993) 9.76
Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution. J Exp Med (1977) 7.89
Complement C3 convertase: cell surface restriction of beta1H control and generation of restriction on neuraminidase-treated cells. Proc Natl Acad Sci U S A (1978) 4.94
Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria. Proc Natl Acad Sci U S A (1983) 3.47
Noninvasive diagnosis of ischemia-induced wall motion abnormalities with the use of high-dose dobutamine stress MRI: comparison with dobutamine stress echocardiography. Circulation (1999) 3.44
A novel sialic acid binding site on factor H mediates serum resistance of sialylated Neisseria gonorrhoeae. J Exp Med (1998) 3.03
Relation of putative thioester bond in C3 to activation of the alternative pathway and the binding of C3b to biological targets of complement. J Exp Med (1980) 2.94
Identification of a 16,600-dalton outer membrane protein on nontypeable Haemophilus influenzae as a target for human serum bactericidal antibody. J Clin Invest (1986) 2.91
Formation of the initial C3 convertase of the alternative complement pathway. Acquisition of C3b-like activities by spontaneous hydrolysis of the putative thioester in native C3. J Exp Med (1981) 2.88
High interlaboratory reproducibility of DNA sequence-based typing of bacteria in a multicenter study. J Clin Microbiol (2006) 2.80
Modulation of cell surface sialic acid expression in Neisseria meningitidis via a transposable genetic element. EMBO J (1996) 2.80
Discrimination between activators and nonactivators of the alternative pathway of complement: regulation via a sialic acid/polyanion binding site on factor H. Proc Natl Acad Sci U S A (1990) 2.79
Prevention of C3 deposition by capsular polysaccharide is a virulence mechanism of type III group B streptococci. Infect Immun (1992) 2.73
Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1994) 2.71
Non-culture diagnosis and serogroup determination of meningococcal B and C infection by a sialyltransferase (siaD) PCR ELISA. Epidemiol Infect (1997) 2.67
Initiation of the alternative pathway of complement: recognition of activators by bound C3b and assembly of the entire pathway from six isolated proteins. Proc Natl Acad Sci U S A (1978) 2.57
Antigenic and physical diversity of Neisseria gonorrhoeae lipooligosaccharides. Infect Immun (1986) 2.55
NZB mouse system for production of monoclonal antibodies to weak bacterial antigens: isolation of an IgG antibody to the polysaccharide capsules of Escherichia coli K1 and group B meningococci. Proc Natl Acad Sci U S A (1985) 2.49
Structural basis of asymmetry in the human immunodeficiency virus type 1 reverse transcriptase heterodimer. Proc Natl Acad Sci U S A (1994) 2.47
Characterization of gonococcal antigens responsible for induction of bactericidal antibody in disseminated infection. J Clin Invest (1977) 2.46
Immunoglobulin G antibodies directed against protein III block killing of serum-resistant Neisseria gonorrhoeae by immune serum. J Exp Med (1986) 2.40
Capsule phase variation in Neisseria meningitidis serogroup B by slipped-strand mispairing in the polysialyltransferase gene (siaD): correlation with bacterial invasion and the outbreak of meningococcal disease. Mol Microbiol (1996) 2.30
Binding of complement factor H to loop 5 of porin protein 1A: a molecular mechanism of serum resistance of nonsialylated Neisseria gonorrhoeae. J Exp Med (1998) 2.24
Crystal structure of a Flp recombinase-Holliday junction complex: assembly of an active oligomer by helix swapping. Mol Cell (2000) 2.24
Genetic alterations in streptomycin-resistant Mycobacterium tuberculosis: mapping of mutations conferring resistance. Antimicrob Agents Chemother (1994) 2.23
Modification by sialic acid of Neisseria gonorrhoeae lipooligosaccharide epitope expression in human urethral exudates: an immunoelectron microscopic analysis. J Infect Dis (1990) 2.22
The phage Mu transpososome core: DNA requirements for assembly and function. EMBO J (1995) 2.14
Characterization of antigens from nontypable Haemophilus influenzae recognized by human bactericidal antibodies. Role of Haemophilus outer membrane proteins. J Clin Invest (1985) 2.09
Disseminated gonococcal infection: a prospective analysis of 49 patients and a review of pathophysiology and immune mechanisms. Medicine (Baltimore) (1983) 2.06
Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine. J Clin Invest (1996) 2.05
Breakdown of C3 after complement activation. Identification of a new fragment C3g, using monoclonal antibodies. J Exp Med (1982) 2.04
Non-O157:H7 pathogenic Shiga toxin-producing Escherichia coli: phenotypic and genetic profiling of virulence traits and evidence for clonality. J Infect Dis (1999) 2.04
The alternative pathway of complement. Springer Semin Immunopathol (1984) 2.01
Intuitive hypertext-based molecular identification of micro-organisms. Lancet (1999) 2.01
The large plasmids of Shiga-toxin-producing Escherichia coli (STEC) are highly variable genetic elements. Microbiology (1999) 1.97
Independent effects of IgG and complement upon human polymorphonuclear leukocyte function. J Immunol (1976) 1.97
The inflammatory cytokine response to Chlamydia trachomatis infection is endotoxin mediated. Infect Immun (1995) 1.94
A cluster of invasive meningococcal disease in young men who have sex with men in Berlin, October 2012 to May 2013. Euro Surveill (2013) 1.93
PspC, a pneumococcal surface protein, binds human factor H. Infect Immun (2001) 1.92
Binding of C4b-binding protein to porin: a molecular mechanism of serum resistance of Neisseria gonorrhoeae. J Exp Med (2001) 1.91
Detection of Mycoplasma pneumoniae by polymerase chain reaction and nonradioactive hybridization in microtiter plates. J Clin Microbiol (1993) 1.91
Identification of three physically and functionally distinct binding sites for C3b in human complement factor H by deletion mutagenesis. Proc Natl Acad Sci U S A (1996) 1.91
Paroxysmal nocturnal hemoglobinuria: deficiency in factor H-like functions of the abnormal erythrocytes. J Exp Med (1983) 1.83
Contribution of genes from the capsule gene complex (cps) to lipooligosaccharide biosynthesis and serum resistance in Neisseria meningitidis. Mol Microbiol (1994) 1.82
Necessity of molecular techniques to distinguish between Neisseria meningitidis strains isolated from patients with meningococcal disease and from their healthy contacts. J Clin Microbiol (1998) 1.80
Mechanisms of neisserial serum resistance. Mol Microbiol (1999) 1.71
An isogenic hemoglobin receptor-deficient mutant of Haemophilus ducreyi is attenuated in the human model of experimental infection. J Infect Dis (2000) 1.69
Molecular divergence of the sia locus in different serogroups of Neisseria meningitidis expressing polysialic acid capsules. Mol Gen Genet (1997) 1.68
Evaluation and long-term outcome of pediatric renovascular hypertension. Pediatr Nephrol (2000) 1.68
Physical heterogeneity of neisserial lipooligosaccharides reflects oligosaccharides that differ in apparent molecular weight, chemical composition, and antigenic expression. Infect Immun (1987) 1.67
Modification of otitis media in chinchillas rechallenged with nontypable Haemophilus influenzae and serological response to outer membrane antigens. J Infect Dis (1985) 1.67
Diagnostics of neisseriaceae and moraxellaceae by ribosomal DNA sequencing: ribosomal differentiation of medical microorganisms. J Clin Microbiol (2001) 1.66
Molecular analysis of the biosynthesis pathway of the alpha-2,8 polysialic acid capsule by Neisseria meningitidis serogroup B. Mol Microbiol (1994) 1.66
Bactericidal antibody response of normal human serum to the lipooligosaccharide of Neisseria gonorrhoeae. J Infect Dis (1986) 1.66
Escherichia coli O157:H7 and O157:H(-) strains that do not produce Shiga toxin: phenotypic and genetic characterization of isolates associated with diarrhea and hemolytic-uremic syndrome. J Clin Microbiol (1999) 1.65
Activation of the alternative complement pathway: recognition of surface structures on activators by bound C3b. J Immunol (1980) 1.65
Complement factor C3 deposition and serum resistance in isogenic capsule and lipooligosaccharide sialic acid mutants of serogroup B Neisseria meningitidis. Infect Immun (1997) 1.65
Evidence-based, interdisciplinary guidelines for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis. Rheumatol Int (2011) 1.64
Neisseria meningitidis porin PorB interacts with mitochondria and protects cells from apoptosis. Proc Natl Acad Sci U S A (2000) 1.64
siaD PCR ELISA for confirmation and identification of serogroup Y and W135 meningococcal infections. FEMS Microbiol Lett (1998) 1.61
Characterization of serum resistance of Neisseria gonorrhoeae that disseminate. Roles of blocking antibody and gonococcal outer membrane proteins. J Clin Invest (1982) 1.60
Experimental Yersinia enterocolitica infection in euthymic and T-cell-deficient athymic nude C57BL/6 mice: comparison of time course, histomorphology, and immune response. Infect Immun (1993) 1.60
DsrA-deficient mutant of Haemophilus ducreyi is impaired in its ability to infect human volunteers. Infect Immun (2001) 1.60
Nucleophilic modification of human complement protein C3: correlation of conformational changes with acquisition of C3b-like functional properties. Biochemistry (1981) 1.58
Underdiagnosis of Chlamydia trachomatis infection. Diagnostic limitations in patients with low-level infection. Sex Transm Dis (1992) 1.57
Cloning of glycoprotein D cDNA, which encodes the major subunit of the Duffy blood group system and the receptor for the Plasmodium vivax malaria parasite. Proc Natl Acad Sci U S A (1993) 1.57
C3b deposition during activation of the alternative complement pathway and the effect of deposition on the activating surface. J Immunol (1983) 1.52
The pathogenesis of gonococcal urethritis in men: confocal and immunoelectron microscopic analysis of urethral exudates from men infected with Neisseria gonorrhoeae. J Infect Dis (1996) 1.52
Natural serum bactericidal activity against Neisseria gonorrhoeae isolates from disseminated, locally invasive, and uncomplicated disease. J Immunol (1980) 1.52
Nephritogenic lambda light chain dimer: a unique human miniautoantibody against complement factor H. J Immunol (1999) 1.51
Species specificity of recognition by the alternative pathway of complement. J Immunol (1985) 1.49
The crystal structure of the catalytic domain of the site-specific recombination enzyme gamma delta resolvase at 2.7 A resolution. Cell (1990) 1.49
Phosphorylation and desensitization of human endothelin A and B receptors. Evidence for G protein-coupled receptor kinase specificity. J Biol Chem (1997) 1.49
Properdin binds to sulfatide [Gal(3-SO4)beta 1-1 Cer] and has a sequence homology with other proteins that bind sulfated glycoconjugates. J Biol Chem (1990) 1.49
Sialic acids of both the capsule and the sialylated lipooligosaccharide of Neisseria meningitis serogroup B are prerequisites for virulence of meningococci in the infant rat. Med Microbiol Immunol (1996) 1.46
Diagnostic and clinical value of anti-cyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis. Ann Rheum Dis (2004) 1.46
Novel engagement of CD14 and multiple toll-like receptors by group B streptococci. J Immunol (2001) 1.46
Dominant active alleles of RIM101 (PRR2) bypass the pH restriction on filamentation of Candida albicans. Mol Cell Biol (2000) 1.43
Acute and long-term effects of booster immunisation on frequencies of antigen-specific memory B-lymphocytes. Vaccine (2001) 1.42
Specificity of the thioester-containing reactive site of human C3 and its significance to complement activation. Biochem J (1994) 1.42
The role of C3 fragments in endocytosis and extracellular cytotoxic reactions by polymorphonuclear leukocytes. Clin Immunol Immunopathol (1982) 1.42
Biosynthesis and glycosylation of the human complement regulatory protein decay-accelerating factor. J Immunol (1986) 1.41
Human vaccination with Escherichia coli J5 mutant induces cross-reactive bactericidal antibody against Neisseria gonorrhoeae lipooligosaccharide. J Infect Dis (1992) 1.41
Molecular basis for distinction of the ET-15 clone within the ET-37 complex of Neisseria meningitidis. J Clin Microbiol (2000) 1.41